Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioLTS:0JQ2 +10.35%24 9-Day RSI is 25.54 as of Jul. 31, 2026. GuruFocus rates LTS:0JQ2 with a GF Score™ of 24/100 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,420 Biotechnology companies, Kala Bio ranks better than 84.93% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-31), Kala Bio's 9-Day RSI is 25.54.
The industry rank for Kala Bio's 9-Day RSI or its related term are showing as below:
LTS:0JQ2's 9-Day RSI is ranked better than 84.93% of 1420
companies
in the Biotechnology industry
Industry Median: 41.82
vs LTS:0JQ2: 25.54
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Kala Bio 9-Day RSI Related Terms
LTS:0JQ2 vs GDTC, GTBP, INAB: 9-Day RSI Comparison
For the Biotechnology subindustry, Kala Bio's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Kala Bio's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kala Bio (LTS:0JQ2) has a 9-Day RSI of 25.54 as of Jul. 31, 2026. According to the industry distribution chart, Kala Bio ranks #214 out of 1420 companies in the Biotechnology industry, placing it in the top 15.1%.
Is Kala Bio's 9-Day RSI too high?
Kala Bio's current 9-Day RSI is 25.54. The Biotechnology industry median 9-Day RSI is 41.82. Kala Bio's value of 25.54 is 38.9% below this industry median. Based on the distribution chart, Kala Bio ranks #214 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kala Bio has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's 9-Day RSI compare to GDTC and GTBP?
According to the Biotechnology industry distribution chart, Kala Bio ranks #214 out of 1420 companies for 9-Day RSI. This places Kala Bio in the top 15% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 41.82. Kala Bio's value of 25.54 is 38.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 41.82, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kala Bio's current 9-Day RSI of 25.54 is 38.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 41.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current 9-Day RSI is 25.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Based on GuruFocus' analysis, Kala Bio (LTS:0JQ2) is currently considered Possible Value Trap. The current 9-Day RSI is 25.54 and 38.9% below the Biotechnology industry median of 41.82. Kala Bio's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Kala Bio (LTS:0JQ2), the current 9-Day RSI is 25.54 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
24GF Score
Get the complete analysis for LTS:0JQ2
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JQ2 has been successfully added to your 
